Melling Nathaniel, Simon Ronald, Mirlacher Martina, Izbicki Jakob R, Stahl Philip, Terracciano Luigi M, Bokemeyer Carsten, Sauter Guido, Marx Andreas H
Department of Surgery, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany.
Institute of Pathology, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany.
Histopathology. 2016 Jan;68(2):191-8. doi: 10.1111/his.12726. Epub 2015 Jul 22.
RNA-binding motif protein 3 (RBM3) has recently been suggested as a prognostic biomarker in an array of human cancers. This study aimed to examine its effects in colorectal cancers.
RBM3 expression was analysed by immunohistochemistry on a tissue microarray containing 1800 colorectal cancers (CRCs). Nuclear RBM3 immunohistochemical staining was found in 95.9% of all interpretable CRCs. Loss of RBM3 expression was linked to advanced tumour stage (P < 0.0001), right-sided tumour localization (P < 0.0001), and poor prognosis (P = 0.0003). In a multivariable analysis including RBM3 staining, tumour grade, tumour stage, and nodal status, only tumour stage and nodal status proved to be independent prognostic markers (P < 0.0001 each), whereas the prognostic impact of RBM3 staining was not significant (P = 0.2655).
Our observations indicate that loss of RBM3 expression is an unfavourable prognostic marker in CRC, and is linked to right-sided tumour localization.
最近有研究表明，RNA结合基序蛋白3（RBM3）可作为多种人类癌症的预后生物标志物。本研究旨在探讨其在结直肠癌中的作用。
通过免疫组织化学方法对包含1800例结直肠癌（CRC）的组织芯片进行RBM3表达分析。在所有可解释的CRC中，95.9%发现有核RBM3免疫组化染色。RBM3表达缺失与肿瘤晚期（P<0.0001）、肿瘤位于右侧（P<0.0001）及预后不良（P = 0.0003）相关。在一项包括RBM3染色、肿瘤分级、肿瘤分期和淋巴结状态的多变量分析中，只有肿瘤分期和淋巴结状态被证明是独立的预后标志物（均为P<0.0001），而RBM3染色的预后影响不显著（P = 0.2655）。
我们的观察结果表明，RBM3表达缺失是CRC的不良预后标志物，且与肿瘤位于右侧有关。
